The DOI matches its Crossref record.
Low Molecular Weight Heparin: Biochemistry, Pharmacology, Perioperative Prophylaxis Regimens, and Guidelines for Regional Anesthetic Management
Abstract
Multiple randomized clinical trials have established the efficacy of standard heparin (SH) anticoagulation for venous thromboembolism prophylaxis. However, for high-risk populations, such as patients undergoing total hip or knee replacement, SH is relatively ineffective and may be associated with significant bleeding complications [1]. Initial animal model studies suggested that low molecular weight fractions of heparin, when administered at equivalent antithrombotic doses, caused less bleeding than SH [2]. These early studies raised the exciting possibility of separating the antithrombotic from the bleeding effects of heparin. The efficacy and safety of low molecular weight heparins (LMWH) as postoperative venous thromboembolism prophylaxis subsequently has been demonstrated in more than 60 clinical trials including more than 20,000 patients [3]. However, reports of spinal hematoma occurring spontaneously and in association with regional anesthesia [4,5] have generated concern regarding the safety of spinal or epidural anesthesia in patients receiving LMWH. In this review, we focus on the biochemistry and pharmacology of LMWH compared with SH, current LMWH prophylaxis regimens, and the implications of perioperative LMWH prophylaxis for anesthesia, particularly among patients receiving regional anesthesia and analgesia. Guidelines will be provided for minimizing the risk of spinal hematoma in patients undergoing regional anesthesia while receiving perioperative anticoagulant-based prophylaxis. Biochemistry and Pharmacology of SH and LMWH SH is a mixture of linear polysaccharide molecules of variable chain lengths (45-50 sugar units) and molecular weights (5,000-30,000 daltons). The mean molecular weight of SH ranges from 12,000 to 15,000 Daltons. Heparin acts as an anticoagulant by binding and catalyzing antithrombin III, a plasma serine protease inhibitor. The heparin-antithrombin III complex inhibits several procoagulant serine proteases, including factors IIa (thrombin), IXa, Xa, XIa, and XIIa (Figure 1).Figure 1: Schematic of the procoagulant system. Circulating procoagulants are shown in ellipses, and activated coagulation factors are shown in rectangles. Heparin catalyzes antithrombin III inhibition of all procoagulant factors enclosed in the rectangles except factor VIIa. Vitamin K-antagonist drugs reduce the plasma activities of factors II (prothrombin), VII, IX, and X. (Reproduced with permission from Horlocker TT, Wedel DJ. Anitcoagulants, antiplatelet therapy, and neuraxis blockade. In: Batra MS, ed. Anesthesiology clinics of North America. Vol 10. Philadelphia: WB Saunders, 1992:3.)Heparin catalytic activity is dependent on both the polysaccharide chain length as well as a specific pentasaccharide sequence within the heparin molecule, which is a high-affinity binding site for antithrombin III. Approximately 30% of SH molecules contain the pentasaccharide high-affinity binding sequence and can catalyze antithrombin III. Heparin chain length partially determines antithrombin III substrate specificity. For example, to efficiently catalyze antithrombin III inhibition of factor IIa (thrombin), a heparin molecule must contain both the pentasaccharide high-affinity binding sequence as well as a chain length of at least 13 additional sugars. Conversely, only the pentasaccharide high-affinity binding sequence is required for heparin to catalyze antithrombin III inhibition of factor Xa. Commercial LMWH is produced by either chemical or enzymatic depolymerization of SH and has a mean molecular weight of 4000-6500 Daltons and a chain length of 13-22 sugars. Consequently, LMWH retains full anti-Xa activity with relatively less anti-IIa (thrombin) activity. The concentration of LMWH is referenced to an international standard and usually expressed as anti-Xa U / mL. The bioavailability and anticoagulant effect of SH is reduced due to binding of SH by plasma and platelet proteins, endothelial cells, and vascular wall matrix proteins [5]. Many of these plasma proteins increase with illness as acute phase reactants (especially factor VIII and von Willebrand factor), which accounts in part for the large interpatient variability in the anticoagulant response to SH. In contrast, LMWH has a much lower affinity for plasma and matrix proteins [6], which results in greater than 90% bioavailability after subcutaneous administration and a very predictable and reproducible anticoagulant response when dosed on a weight-adjusted basis. Consequently, neither laboratory monitoring of the anticoagulant response to LMWH (anti-Xa levels) nor dose adjustment is necessary. Peak anti-Xa activity occurs 3-4 h after a subcutaneous LMWH injection, and 12-h anti-Xa levels are approximately 50% of peak levels. The clearance of SH is dose-dependent and occurs through a saturable mechanism due to binding by plasma proteins and endothelial cells, and a slower nonsaturable renal clearance. Because LMWH is not highly protein- or endothelial c
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationHorlocker, T. (2003) · Regional Anesthesia and Pain Medicine · doi:10.1053/rapm.2003.50046 · Cited by 921
Self-citationNarouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Crowhurst, J. A., & Plaat, F. (1999) · Anaesthesia · doi:10.1046/j.1365-2044.1999.00854.x · Cited by 334
Investigation and management of heritable thrombophilia
Walker, I. D., Greaves, M., & Preston, F. E. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02981.x · Cited by 299
Metadata
- Authors
- Horlocker, T. T., & Heit, J. A.
- Venue
- Anesthesia & Analgesia
- Published
- 1997-10
- Volume
- 85
- Issue
- 4
- Pages
- 874-885
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W2001204795
- Cited by
- 231
- References
- 0
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low Molecular Weight Heparin: Biochemistry, Pharmacology, Perioperative Prophylaxis Regimens, and Guidelines for Regional Anesthetic Management. https://app.cochat.ai/papers/10.1097/00000539-199710000-00031
- The paper
- Horlocker, T. T., & Heit, J. A. (1997). Low Molecular Weight Heparin: Biochemistry, Pharmacology, Perioperative Prophylaxis Regimens, and Guidelines for Regional Anesthetic Management. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199710000-00031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.